10.05
+0.26(+2.66%)
Currency In USD
| Previous Close | 9.79 |
| Open | 9.74 |
| Day High | 10.2 |
| Day Low | 9.74 |
| 52-Week High | 10.75 |
| 52-Week Low | 4.52 |
| Volume | 15,555 |
| Average Volume | 25,660 |
| Market Cap | 90.92M |
| PE | -143.57 |
| EPS | -0.07 |
| Moving Average 50 Days | 8.16 |
| Moving Average 200 Days | 6.63 |
| Change | 0.26 |
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
GlobeNewswire Inc.
Feb 18, 2026 1:37 PM GMT
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ETPORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and market
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
GlobeNewswire Inc.
Jan 07, 2026 1:10 PM GMT
Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ETPORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and market
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
GlobeNewswire Inc.
Dec 24, 2025 6:05 PM GMT
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it recei